Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Biotech/Pharma Business
-
By Donald Zuhn — On March 21, 2007, Aegerion Pharmaceuticals Inc. filed a registration statement with the Securities and Exchange Commission (SEC) for a proposed initial public offering of its common stock. According to a Reuters report, while neither the number of shares in the offering nor the offering price have been determined,…
-
By Christopher P. Singer — Ocean Tomo® will hold its first live intellectual property auction of 2007 in Chicago on April 18-19. It’s first two auction events, held in April and October 2006, resulted in $8.5 million and $23 million of transactions, respectively. The auction is held much the same as a traditional…
-
By Donald Zuhn — Last Friday, NimbleGen Systems, Inc. announced that it had filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. According to NimbleGen’s press release, neither the number of shares nor the offering price had yet been determined. MarketWatch and…
-
By Christopher P. Singer — Patent Docs was given the opportunity to review a recently-published book by patent attorney M. Henry Heines, Ph.D., titled "Patents for Business: The Manager’s Guide to Scope, Strategy, and Due Diligence" (Praeger Publishers, Westport, CT (2007)). In his text, Dr. Heines provides an easy-to-read overview of intellectual property…
-
By Donald Zuhn As noted by Patent Docs earlier this week, a recent article at BusinessWeek.com has issued a poor prognosis for biotech IPO’s. If the events of the past week are any indication, rumors of the "demise" of biotech IPO’s may have been greatly exaggerated. On Tuesday, Rosetta Genomics announced that its…
-
By Donald Zuhn An article at BusinessWeek.com ("Biotech IPO’s Iffy Prognosis") attributes a recent drop in initial public offerings (IPO’s) for small biotech companies to the reluctance of investors to forgo big paydays as small biotechs use much of the cash raised from such offerings on drug development. However, while the biotech IPO…
-
By Christopher P. Singer In keeping with the spirit of Hollywood’s award season, Brian Lawler, a contributor to The Motley Fool wrote up his list of biotech "winners" for 2006. The article provides a nice snapshot of a few of the biotech stories over the past year. Using categories more familiar to Hollywood…
-
By Christopher P. Singer — In a February 7, 2007 Wall Street Journal article entitled: "Small Firms Seek to Profit From Drug Giants' Castoffs" (subscription required), Jeanne Whalen discusses a drug development strategy that is more frequently being employed by small drug companies. In particular, smaller companies employing this strategy enter into agreements…
-
By Christopher P. Singer — In a February 5, 2007 press release Cell Genesys announced that it has secured a Committed Equity Financing Facility (CEFF) of up to $75 million with institutional investor Kingsbridge Capital Limited. The financing will derive from the sale of newly issued common shares of stock from Cell Genesys…
-
By Jason Derry — PharmaLive has reported that Vanderbilt-Ingram Cancer Center and the University of Michigan added their names to the list of members currently involved in Sigma-Aldrich's RNAi Partnership Program. The Program was set up by Sigma-Aldrich to provide members with access to its functional genomics portfolio, which comprises shRNA libraries that…
Patent Docs 